Humanin: A Comprehensive Research Monograph

Overview

Humanin is a 24-amino acid peptide encoded within the mitochondrial 16S ribosomal RNA gene (MT-RNR2). It was discovered in 2001 by Hashimoto, Niikura, and colleagues through a functional expression screening of a cDNA library derived from the occipital lobe of a patient with Alzheimer’s disease. The screen was designed to identify factors capable of rescuing neuronal cells from death induced by familial Alzheimer’s disease (FAD) mutant genes, and humanin emerged as a potent neuroprotective agent that abolished cell death caused by multiple distinct FAD gene products as well as amyloid-beta (A-beta) peptides. . . ().

The amino acid sequence of humanin is Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala (MAPRGFSCLLLLTSEIDLPVKRRA), with a molecular weight of approximately 2687 Da. The peptide is produced as a secreted factor — following translation, it is released into the extracellular space where it exerts both autocrine and paracrine cytoprotective effects. The discovery of humanin represented the first identification of a functional peptide encoded within the mitochondrial genome in over three decades, fundamentally expanding the understood coding capacity of mitochondrial DNA.

Humanin is now recognized as the founding member of a novel class of bioactive molecules termed mitochondrial-derived peptides (MDPs). This family has since grown to include MOTS-c (encoded within the mitochondrial 12S rRNA gene) and the small humanin-like peptides (SHLPs 1-6), all of which are encoded in the 16S rRNA region alongside humanin. . . (). Together, the MDPs have emerged as key retrograde signaling molecules through which mitochondria communicate with the nucleus and with distant tissues, functioning as endocrine factors detectable in circulating blood.

One of the most significant findings in humanin biology is that circulating levels decline progressively with age across multiple species. This age-dependent decline has been correlated with increasing vulnerability to neurodegenerative disease, metabolic dysfunction, and cardiovascular pathology. Conversely, studies of exceptional longevity have revealed that children of centenarians possess significantly higher circulating humanin levels compared to age-matched controls, suggesting that sustained humanin production may be a biomarker — and potentially a mediator — of healthy aging. . . ().

A key tool in humanin research is S14G-Humanin (also designated HNG or Humanin G), a synthetic analog in which the serine residue at position 14 is replaced with glycine. This single substitution renders HNG approximately 1000-fold more potent than native humanin in cytoprotective assays, making it the preferred compound for in vivo studies where higher potency enables lower dosing and more robust biological effects.

Mechanism of Action

Humanin exerts its cytoprotective and metabolic effects through multiple distinct but interconnected molecular pathways. Unlike many bioactive peptides that operate through a single receptor system, humanin engages at least four major mechanistic axes: direct inhibition of mitochondrial apoptosis through BAX and BID sequestration, modulation of IGF signaling via IGFBP-3 binding, activation of canonical survival cascades through a trimeric cell-surface receptor, and signaling through formyl peptide receptor-like receptors.

BAX and BID Sequestration — Direct Anti-Apoptotic Action

The most thoroughly characterized mechanism of humanin is its direct physical interaction with BAX, a pro-apoptotic member of the BCL-2 protein family. BAX normally resides in an inactive conformation in the cytosol. Upon receiving death signals, BAX undergoes conformational changes that expose its membrane-targeting domains, resulting in translocation to the mitochondrial outer membrane where it oligomerizes to form pores. These pores cause mitochondrial outer-membrane permeabilization (MOMP), releasing cytochrome c and other apoptogenic factors into the cytosol and committing the cell to apoptosis.

Guo and colleagues demonstrated in a landmark 2003 publication in Nature that humanin binds directly to BAX and prevents this critical translocation step. The interaction is specific: reducing endogenous humanin expression using small interfering RNAs sensitized cells to BAX-mediated death and increased BAX translocation to mitochondrial membranes. Conversely, exogenous humanin blocked BAX association with isolated mitochondria and suppressed cytochrome c release in cell-free systems. . . ().

Subsequent work by Morris et al. revealed the structural basis of this interaction in greater detail. Using light-scattering, circular dichroism, and fluorescence spectroscopy, they demonstrated that humanin induces conformational changes in BAX and co-assembles with it into fibrillar structures. This sequestration into fibers physically prevents BAX from inserting into the mitochondrial outer membrane. Critically, humanin mutations known to abolish its anti-apoptotic activity also altered fiber morphology, establishing a direct structure-function relationship. . . ().

Humanin also interacts with BID, another pro-apoptotic BCL-2 family member that cooperates with BAX to promote MOMP. Single-molecule fluorescence studies by Ma and Liu demonstrated that humanin inhibits the membrane association of both Bax and truncated Bid (tBid), prevents tBid-induced Bax tetramerization in lipid bilayers, and blocks the downstream pore-forming oligomerization that is essential for cytochrome c release. . . ().

IGFBP-3 Binding and IGF-1 Axis Modulation

The interaction between humanin and insulin-like growth factor binding protein-3 (IGFBP-3) was identified through a yeast two-hybrid screen and subsequently confirmed through multiple biochemical approaches including co-immunoprecipitation, pull-down assays, and ligand blotting. Ikonen, Liu, Hashimoto, and Cohen demonstrated that this interaction is of high affinity and specificity, with humanin binding to the heparin-binding domain of IGFBP-3 at a site distinct from the IGF-I binding interface. . . ().

The functional consequences of this interaction are complex and context-dependent. In some cellular contexts, humanin inhibited IGFBP-3-induced apoptosis, while in primary cortical neurons, IGFBP-3 markedly potentiated humanin’s rescue ability against amyloid-beta toxicity. This dual nature — both synergistic and antagonistic depending on cell type — suggests that the humanin-IGFBP-3 axis functions as a fine-tuning mechanism for cell survival decisions.

At the systemic level, humanin treatment decreases circulating IGF-1 levels, and reciprocally, IGF-1 appears to regulate humanin levels. This bidirectional regulatory relationship positions humanin at the intersection of the growth hormone / IGF-1 signaling axis, one of the most evolutionarily conserved longevity pathways. . . (). The IGF-1-lowering effect of humanin may partially explain its lifespan-extending properties, as reduced IGF-1 signaling is a hallmark of caloric restriction and genetic models of extended longevity.

Trimeric Receptor Complex — STAT3, AKT, and ERK1/2 Activation

In addition to its intracellular targets, humanin acts as an extracellular ligand for a trimeric cell-surface receptor complex composed of gp130 (glycoprotein 130), CNTFR (ciliary neurotrophic factor receptor), and WSX-1 (also known as IL-27Ralpha). Activation of this receptor complex engages three major intracellular survival cascades.

Kim, Guerrero, and colleagues demonstrated that humanin treatment increases phosphorylation of AKT, ERK1/2, and STAT3 through PI3K, MEK, and JAK signaling intermediaries, respectively. These three pathways — each independently associated with cell survival, proliferation, and stress resistance — converge to provide robust cytoprotection. . . ().

A particularly notable finding from this work was that humanin’s in vivo signaling activity in the hippocampus is age-dependent. When old mice were injected with humanin, significant increases in AKT and ERK1/2 phosphorylation were observed in hippocampal tissue. Young mice showed no such response. This age-dependent responsiveness suggests that humanin may function as a compensatory protective factor whose signaling becomes more pronounced — or more necessary — as age-related damage accumulates in the brain.

Formyl Peptide Receptor-Like Signaling

Humanin has also been identified as a ligand for FPRL1 and FPRL2 (formyl peptide receptor-like 1 and 2), members of the G protein-coupled receptor family that mediate chemotaxis and immune cell activation. While this signaling axis is less extensively characterized than the others, it may contribute to humanin’s anti-inflammatory effects and its role in regulating immune cell behavior, including the recently described promotion of efferocytosis (the clearance of apoptotic cells by macrophages) and resolution of inflammation.

Pharmacokinetics

The pharmacokinetic profile of humanin has been characterized primarily through preclinical studies and circulating level measurements in human populations. Comprehensive single-dose pharmacokinetic studies with full compartmental modeling remain limited in the published literature.

Endogenous Production and Circulation

Humanin is constitutively expressed in multiple tissues with high metabolic activity, including brain, heart, liver, kidney, skeletal muscle, and vascular endothelium. . . (). In the central nervous system, humanin expression has been localized to both neurons and glial cells, with astrocytes identified as a major source of secreted humanin in the brain. . . (). The peptide is detectable in circulating blood as a secreted endocrine factor.

Circulating humanin levels in humans typically range from the low picomolar to nanomolar range and exhibit significant inter-individual variation. Levels decline with age in a manner that parallels increasing disease susceptibility. In a study of exceptional longevity, Yen, Cohen, Barzilai, and colleagues found that children of centenarians had circulating humanin levels significantly higher than age-matched controls, while patients with Alzheimer’s disease and MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) had reduced levels. . . ().

Exogenous Administration

In preclinical studies, humanin and its analogs (particularly HNG) have been administered via intraperitoneal (ip), subcutaneous (sc), intravenous (iv), intracerebroventricular (icv), and intranasal routes. The intranasal route is of particular interest for neuroprotection applications, as Kim demonstrated that intranasally delivered humanin reaches the brain primarily via trigeminal nerve pathways, providing direct CNS access without the need for systemic exposure or invasive delivery. . . ().

Half-Life and Dosing Considerations

Precise plasma half-life values for humanin have not been definitively established in published literature. The native peptide, as a small 24-amino acid molecule, is expected to be subject to proteolytic degradation and renal clearance. In practice, the enhanced potency of the S14G analog (HNG) compensates for pharmacokinetic limitations by achieving effective tissue concentrations at much lower doses than native humanin. Most preclinical dosing regimens employ daily or twice-weekly administration, suggesting a functional duration of action that is shorter than the dosing interval.

Research Applications

Neuroprotection and Alzheimer’s Disease

Neuroprotection is the foundational research application of humanin, stemming directly from its discovery as a factor that rescues neurons from Alzheimer’s disease-associated insults. Hashimoto’s original functional screen demonstrated that humanin abolished neuronal cell death caused by mutant forms of amyloid precursor protein (APP), presenilin 1 (PS1), presenilin 2 (PS2), and amyloid-beta peptides — encompassing the major genetic and molecular drivers of familial Alzheimer’s disease. . . ().

Subsequent work has expanded the scope of humanin’s neuroprotective profile considerably. Niikura, one of the original co-discoverers, reviewed the accumulated evidence and noted that humanin exhibits both intracellular and extracellular anti-cell death actions and antagonizes multiple AD-associated pathomechanisms, including amyloid plaque accumulation, tau hyperphosphorylation, and oxidative damage to neuronal mitochondria. . . ().

In the hippocampus specifically, astrocyte-derived humanin has been shown to prevent glutamate-induced dendritic atrophy and synaptic loss. Zarate and colleagues demonstrated that humanin prevented reductions in synaptophysin puncta number and total puncta area in hippocampal neuron cultures exposed to excitotoxic insults, suggesting a role in maintaining structural synaptic plasticity — a process central to memory formation and cognitive function. . . ().

Beyond Alzheimer’s disease, humanin has demonstrated neuroprotective efficacy in models of Parkinson’s disease. Intranasal delivery of humanin resulted in behavioral recovery and neuroprotection in neurotoxic mouse models of PD, with the peptide activating PI3K/AKT signaling and enhancing mitochondrial biogenesis — including upregulation of mitochondrial gene expression encompassing humanin itself, creating a positive feedback loop for mitochondrial protection. . . ().

Aging and Longevity

The relationship between humanin and lifespan was established in a landmark 2020 study by Yen, Cohen, Barzilai, and colleagues that spanned multiple species and experimental paradigms. In C. elegans, overexpression of humanin was sufficient to increase lifespan in a daf-16-dependent manner, linking humanin directly to the insulin/IGF-1 signaling pathway that is the most conserved longevity mechanism across metazoans. In humanin transgenic mice, multiple healthspan-related phenotypes overlapped with the worm findings, including increased protection against toxic insults. . . ().

Treatment of middle-aged mice with the potent analog HNG twice weekly improved metabolic healthspan parameters and reduced inflammatory markers, demonstrating that exogenous humanin supplementation could partially reverse age-related metabolic decline. Cross-species analyses revealed that while humanin levels generally decline with age, they are surprisingly stable in the naked mole-rat (Heterocephalus glaber), a rodent species that exhibits negligible senescence and an extraordinarily long lifespan relative to its body size.

In human populations, circulating humanin was decreased in patients with Alzheimer’s disease and MELAS, while children of centenarians — individuals with a genetic predisposition toward exceptional longevity — had substantially higher circulating humanin levels than age-matched controls. Together, these observations establish humanin as both a biomarker and a potential mediator of healthy aging across the phylogenetic spectrum.

Metabolic Regulation and Diabetes

Humanin has emerged as a significant regulator of glucose metabolism and insulin sensitivity. The peptide increases peripheral insulin sensitivity, improves pancreatic beta-cell survival under stress conditions, and modulates hepatic glucose production. Boutari and colleagues reviewed the in vitro and in vivo evidence linking humanin to diabetes mellitus and concluded that the peptide’s insulin-sensitizing and beta-cell-protective actions position it as a potential therapeutic for type 2 diabetes, a condition increasingly recognized as an age-related metabolic disease. . . ().

The connection between humanin and the MDP family’s metabolic roles was further elaborated by Cobb, Cohen, and colleagues, who identified the small humanin-like peptides (SHLPs 1-6) encoded alongside humanin in the mitochondrial 16S rRNA region. Using hyperinsulinemic-euglycemic clamp studies, they demonstrated that intracerebrally infused SHLP2 increased glucose uptake and suppressed hepatic glucose production, establishing that multiple MDPs from the humanin locus function as insulin sensitizers. Circulating SHLP2, like humanin, declined with age, reinforcing the concept that the aging-related loss of mitochondrial-derived peptides contributes to metabolic deterioration. . . ().

The potent humanin analog HNG has also been shown to suppress circulating IGF-1 levels, leading investigators to characterize it as a caloric restriction mimetic — a compound that recapitulates the metabolic and longevity benefits of reduced caloric intake without actual dietary restriction. . . ().

Cardiovascular Protection

Humanin is endogenously expressed in human vascular endothelium, and exogenous administration protects vascular cells from oxidative damage — a central driver of atherosclerosis. Bachar, Lerman, Cohen, and colleagues demonstrated that humanin is present in the endothelial cell layer of human internal mammary arteries, atherosclerotic coronary arteries, and saphenous veins. In human aortic endothelial cell cultures, pretreatment with 0.1 micromolar humanin reduced oxidized LDL-induced reactive oxygen species formation by approximately 50%, apoptosis by approximately 50%, and ceramide formation (a lipid second messenger in apoptosis signaling) by approximately 20%. . . ().

In myocardial ischemia-reperfusion (I/R) injury models, humanin has demonstrated consistent cardioprotective effects. Gong, Goetzman, and Muzumdar reviewed the evidence and identified multiple mechanisms through which humanin protects the myocardium following I/R injury, including attenuation of oxidative stress, reduction of endoplasmic reticulum stress, modulation of autophagy, and inhibition of mitochondria-mediated apoptosis. The convergence of these pathways makes humanin a multitarget cardioprotective agent rather than a single-mechanism drug candidate. . . ().

Chemoprotection and Cancer Research

An intriguing application of humanin analogs is in the protection of normal tissues during cancer chemotherapy. Lue, Swerdloff, Wang, Cohen, and colleagues demonstrated that HNG protected male germ cells and leucocytes from cyclophosphamide-induced damage in tumor-bearing mice without interfering with — and in fact enhancing — chemotherapy-induced suppression of cancer metastases. HNG alone reduced lung metastases, and the combination of HNG with cyclophosphamide produced greater metastasis suppression than either agent alone. . . ().

This dual action — protecting normal cells while not promoting (and potentially inhibiting) cancer cell survival — distinguishes humanin from conventional cytoprotective agents and suggests a selective mechanism based on the differing metabolic and apoptotic regulation of normal versus malignant cells. The observation that HNG suppresses circulating IGF-1 may contribute to its anti-metastatic effects, as IGF-1 signaling promotes cancer cell proliferation and survival in many tumor types.

Safety Profile

Humanin and its analogs have demonstrated a favorable safety profile across the published preclinical literature. As an endogenous mitochondrial-derived peptide constitutively expressed in human tissues, humanin benefits from a theoretical safety advantage over entirely synthetic compounds.

Preclinical Safety Data

In rodent studies employing daily or twice-weekly dosing of HNG over periods ranging from days to weeks, no significant adverse effects have been reported in the published literature. The 2020 Yen et al. study, which administered HNG to middle-aged mice twice weekly over an extended period, documented improved metabolic parameters and reduced inflammatory markers with no reported toxicity. . . ().

The chemoprotection studies by Lue et al. are particularly informative for safety assessment, as they demonstrated that HNG treatment did not interfere with the anti-tumor efficacy of cyclophosphamide and in fact enhanced cancer metastasis suppression. This selective protection of normal cells over malignant cells is reassuring from a safety standpoint. . . ().

Immunogenicity

As a 24-amino acid peptide derived from an endogenous mitochondrial sequence, humanin is expected to have low immunogenic potential. No published studies have reported antibody formation or hypersensitivity reactions following repeated administration.

Dosing in Research

The following table summarizes dosing parameters from key published humanin and HNG studies across various experimental models.

Molecular Properties

Storage and Handling

Humanin should be stored as lyophilized powder at -20C or below for long-term stability, where it is expected to remain stable for extended periods (typically 1-2 years). Reconstituted solutions should be stored at 2-8C and used within 14 days, or aliquoted into single-use volumes and stored at -20C for up to 30 days. Avoid repeated freeze-thaw cycles, as this may promote peptide degradation and aggregation.

The lyophilized powder should be protected from light and moisture. Vials should be equilibrated to room temperature before opening to prevent moisture condensation on the peptide cake. Reconstitution is typically performed using sterile water or bacteriostatic water. If solubility is limited at neutral pH, a small volume of dilute acetic acid (0.1%) may be added before diluting to the final working concentration with aqueous buffer.

For research applications requiring precise concentration determination, UV absorbance at 205 nm or amino acid analysis is recommended, as humanin lacks tryptophan residues (the standard A280 method is unreliable for peptides without aromatic residues).

Current Research Landscape

Humanin research has expanded dramatically since its discovery in 2001, evolving from a single neuroprotective factor into the founding member of an entirely new class of mitochondrial signaling molecules. Key areas of active investigation include:

1. Clinical translation and biomarker development: Circulating humanin levels are increasingly studied as a biomarker of biological aging, mitochondrial function, and disease risk. Large-cohort epidemiological studies correlating humanin levels with disease incidence and mortality outcomes represent a critical step toward clinical application. The validation of humanin as a diagnostic or prognostic biomarker could precede its development as a therapeutic agent.

2. Intranasal delivery for neurodegeneration: The demonstration that intranasally administered humanin reaches the brain via trigeminal pathways . . (). has opened a practical route to CNS-targeted delivery without blood-brain barrier crossing. Optimization of intranasal formulations for sustained release and enhanced bioavailability is an active area of pharmaceutical development.

3. Combination with other MDPs: The discovery that humanin, MOTS-c, and SHLPs 1-6 are all encoded in mitochondrial DNA and share cytoprotective properties raises the possibility of synergistic combination strategies. MOTS-c, which primarily targets metabolic pathways through AMPK activation, may complement humanin’s anti-apoptotic and neuroprotective actions.

4. Analog development: While HNG (S14G) represents the current gold-standard analog, novel synthetic humanin derivatives with improved pharmacokinetic properties, enhanced tissue selectivity, or resistance to proteolytic degradation are under active development. Cyclic analogs and peptidomimetics based on the humanin pharmacophore may extend the translational potential of this peptide class.

5. Mitochondrial retrograde signaling: Humanin’s role as a retrograde signal — a message from mitochondria to the nucleus and to distant tissues — places it at the center of fundamental questions about mitochondrial communication in health and disease. Understanding how mitochondrial stress regulates humanin transcription and secretion, and how circulating humanin feeds back to mitochondrial function, remains an important basic science question.

6. Chemoprotective adjuvant therapy: The finding that HNG protects normal tissues during chemotherapy while enhancing tumor suppression . . (). represents a highly translatable application. Future studies are expected to investigate humanin analogs as adjuvant agents across multiple chemotherapy regimens and cancer types.

References

The studies referenced throughout this monograph represent a subset of the published literature on humanin. For a comprehensive bibliography, researchers are encouraged to search PubMed using the terms “humanin,” “S14G-humanin,” “HNG,” or “mitochondrial-derived peptides” for the most current publications.